Patent ID: 8193172
Filing Date: 2012-06-05
Classification: A61K,A61P

Abstract:
1. A method for treatment with the compound (11β, 17β)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one of a patient suffering from major depressive disorder by determining, prior to treatment, a peripheral cortisol level at a selected time of day, then measuring peripheral cortisol level, at the selected time of day, after administering at least one daily dose of the compound to the patient, and continuing administration of the compound with a daily dose which, on the basis of corresponding daily measurements of peripheral cortisol level, is determined to be the highest daily dose that does not increase the peripheral cortisol level beyond the peripheral cortisol level measured prior to treatment.